IRIS Institutional Research Information System - OPENBS Open Archive UniBS

SACCHETTI, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.376
AS - Asia 5.690
EU - Europa 5.293
SA - Sud America 896
AF - Africa 149
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 13
Totale 24.449
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.185
CN - Cina 2.266
SG - Singapore 1.736
IT - Italia 1.274
UA - Ucraina 1.219
BR - Brasile 753
HK - Hong Kong 663
DE - Germania 645
PL - Polonia 403
GB - Regno Unito 385
FR - Francia 319
FI - Finlandia 318
VN - Vietnam 281
RU - Federazione Russa 242
IN - India 229
TR - Turchia 199
IE - Irlanda 196
CA - Canada 104
SE - Svezia 68
AR - Argentina 61
BD - Bangladesh 59
MX - Messico 51
ZA - Sudafrica 48
CZ - Repubblica Ceca 44
NL - Olanda 44
BE - Belgio 43
JP - Giappone 37
ID - Indonesia 35
SA - Arabia Saudita 31
NG - Nigeria 29
IQ - Iraq 27
AU - Australia 23
EC - Ecuador 23
ES - Italia 23
PK - Pakistan 21
IR - Iran 19
MA - Marocco 16
UZ - Uzbekistan 16
CO - Colombia 14
EU - Europa 12
JM - Giamaica 12
LT - Lituania 12
VE - Venezuela 12
CH - Svizzera 11
KE - Kenya 11
AT - Austria 10
EG - Egitto 10
MU - Mauritius 10
PH - Filippine 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
GR - Grecia 8
NZ - Nuova Zelanda 8
PY - Paraguay 8
PT - Portogallo 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
DZ - Algeria 6
AL - Albania 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
BH - Bahrain 4
IL - Israele 4
PA - Panama 4
PS - Palestinian Territory 4
SI - Slovenia 4
SV - El Salvador 4
AM - Armenia 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
ET - Etiopia 3
KR - Corea 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
TH - Thailandia 3
AO - Angola 2
BB - Barbados 2
CR - Costa Rica 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
OM - Oman 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
Totale 24.436
Salva come PNG Salva come JPEG
Città #
Fairfield 1.347
Woodbridge 1.195
Ashburn 1.009
Singapore 947
Jacksonville 895
Houston 818
Hong Kong 660
Ann Arbor 606
Chandler 588
Seattle 536
Cambridge 514
Wilmington 483
Beijing 422
Warsaw 400
The Dalles 364
Princeton 358
New York 333
Nanjing 320
San Jose 304
Dublin 192
Helsinki 174
Brescia 163
Istanbul 156
Lauterbourg 154
Los Angeles 152
Milan 136
Nanchang 120
Lancaster 101
Shenyang 101
Des Moines 96
Dearborn 94
Ho Chi Minh City 92
Changsha 90
Hebei 89
Jinan 86
Moscow 79
Munich 77
Tianjin 77
Buffalo 76
Dallas 69
São Paulo 64
Shanghai 63
Redondo Beach 56
San Francisco 56
Chicago 55
Jiaxing 53
San Diego 50
Hanoi 49
Boardman 46
Council Bluffs 43
Santa Clara 40
Hangzhou 38
London 38
Ningbo 38
Orem 37
Washington 37
Rome 36
Tokyo 36
Zhengzhou 35
San Mateo 33
Inzago 32
Guangzhou 31
Lanzhou 31
Montreal 31
Frankfurt am Main 30
Rio de Janeiro 30
Abuja 29
Toronto 29
Brussels 28
Norwalk 28
Taizhou 27
Turku 27
Chennai 26
Brno 25
Kunming 25
Brooklyn 24
Denver 24
Leawood 24
Romola 24
Verona 23
Haikou 21
Johannesburg 21
Atlanta 20
Mexico City 19
Stockholm 19
Augusta 18
Mantova 18
Riyadh 18
Belo Horizonte 17
Boston 17
Brugherio 17
Taiyuan 17
Olomouc 15
Phoenix 15
Bareggio 14
Berchem 14
Candia 14
Dong Ket 14
Hefei 14
Mumbai 14
Totale 16.260
Salva come PNG Salva come JPEG
Nome #
Analysis of DTI brain data and implementation in a novel software (DTILAB) 911
Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways 320
New Copy Number Variations in Schizophrenia 317
Compound heterozygosity for a large CNV deletion and a rare missense mutation in the FSTL5 gene of a patient affected by schizophrenia. 301
The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies 258
Predictors of cognitive improvement and normalization under cognitive remediation in patients with schizophrenia. 237
Is structured group psychoeducation for bipolar patients effective in ordinary mental health services? A controlled trial in Italy 235
Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia 225
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. 203
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 197
Adult ADHD: Prevalence and Clinical Correlates in a Sample of Italian Psychiatric Outpatients 194
Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia 186
Gene per la neuregulina 1 e schizofrenia: ulteriori evidenze di associazione 185
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. 184
The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia 184
Comparison of quetiapine, olanzapine and risperidone in schizophrenia. 184
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 182
Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting 180
A STUDY OF EFFECTIVENESS OF STRUCTURED GROUP PSYCHOEDUCATION FOR BIPOLAR PATIENTS. A CONTROLLED TRIAL IN ITALY 180
Combined measure of smooth pursuit eye movements and ventricle-brain ratio in schizophrenic disorders. 178
A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. 175
Does cognitive remediation modify the use of psychiatric services and the patterns of care of patients with schizophrenia? 175
Cognitive remediation in schizophrenia. 175
Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia 174
Comparison of quetiapine (‘Seroquel’), olanzapine and risperidone in a randomized study in patients with schizophrenia. 173
Analysis of Copy Number Variations in Schizophrenia Italian Patients 171
Comparison of Quetiapine, Olanzapine, and Risperidone in Patients With Schizophrenia: Interim Results of a Randomised, Rater-blinded Study. 171
Functional study of a novel homozygous mutation in the GAD1 gene, detected in a patient with schizophrenia. 168
Schizotassia 165
A genome-wide pharmacogenomic study of patients with schizophrenia suggests that GRM7 mediates the effects of risperidone on positive symptoms 165
Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies 164
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis 164
Interim results of a randomised, rater-blinded study comparing quetiapine, olanzapine and risperidone in patients with schizophrenia. 163
At-risk gambling in patients with severe mental illness. Prevalence and associated features. 162
Virological and immunological study of schizophrenic patients in relation to CT scan abnormality. 160
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. 158
Adherence to antipsychotics in schizophrenia. 158
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study 157
Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: A prospective controlled study in a real-world setting. 156
Depressive disorders and personality variables in HIV positive and negative intravenous drug-users 155
The role of the cytochine network in schizophrenia: an overview. 154
Are SSRI antidepressants a clinically homogeneous class of compounds? 153
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia 152
Well-being in patients with schizophrenia, mood and personality disorders attending psychiatric services in the community. A controlled study 152
Cognitive remediation in schizophrenia: a controlled study 151
Persistence of effectiveness of cognitive remediation interventions in schizophrenia: A 1-year follow-up study. 151
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis 150
Brain morphology in schizophrenic disorder: prevalence and correlates of diffuse (cortical and subcortical) brain atrophy. 148
A multimodal imaging study of never-medicated adults with schizophrenia 148
Patterns of Brain Structural Changes in First-Contact, Antipsychotic Drug-Naive Patients with Schizophrenia. 147
Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: Evidence from a naturalistic, retrospective, 18-month follow-up study. 145
Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients 145
Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study. 145
Exome sequencing of schizophrenia patients with high level of homozygosity identifies a homozygous novel mutation that reduces the glutamate acid decarboxylase 67 (GAD67) activity 145
Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. 144
Season of birth and cerebral ventricular enlargement in schizophrenia 144
Self-ordered pointing and visual conditional associative learning tasks in drug-free schizophrenia spectrum disorder patients. 142
Additional Evidence for White Matter Damage in Never-Medicated Adults with Schizophrenia and Schizophreniform Disorder 142
Post-traumatic stress disorder and subthreshold post-traumatic stress disorder in recent male asylum seekers: An expected but overlooked “European” epidemic 142
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. 141
Fertility and marital status in mood disorders: relationship with age at onset. 141
Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma 141
Cortical atrophy in schizophrenia: prevalence and associated features 140
Non pharmacological strategies to enhance adherence and continuity of care in schizophrenia. 140
Association study between schizophrenia and the AMPA genes GRIA1, GRIA2 AND GRIA4 139
CT scan abnormalities and outcome of chronic schizophrenia 139
Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies 139
Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients 139
Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. 138
Carlo Lorenzo Cazzullo (1915-2010): father of Italian psychiatry 137
Negative symptom severity at discharge from an index hospitalization and subsequent use of psychiatric care resources: A retrospective 1-year follow-up study on 450 patients with schizophrenia spectrum disorders 137
Cytokine profiles in drug-naive schizophrenic patients. 136
Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample 136
La cognitività sociale nella schizofrenia: modelli interpretativi e strategie di intervento 135
Early life events and affective disorder revisited. 134
Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. 134
Developmental brain abnormalities in schizophrenia: contributions of genetic and perinatal factors. 133
Change in core symptoms of borderline personality disorder by tDCS: A pilot study 133
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients 133
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. 132
Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. 131
Antipsychotics, antidepressants, anticonvulsants, and placebo on symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials 131
CLINICAL ASSESSMENT OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA THROUGH THE SCHIZOPHRENIA COGNITION RATING SCALE: A VALIDATION STUDY IN THE ITALIAN POPULATION 131
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. 130
Variables Associated With General Practitioners' Knowledge About and Diagnostic Skills for Schizophrenia 129
Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review 129
Immediate and 8-Month Impact of a Medical Educational Course for General Practitioners on Knowledge About Schizophrenia and Its Treatment: Results of a 3-Phase Study From Brescia, Italy. 128
Detection of high level of autozygosity in a group of Italian schizophrenia patients 128
Whole exome sequencing of schizophrenia patients with high level of autozygosity. 128
Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. 127
Structural brain abnormalities in bipolar disorder: what meta-analyses tell us 127
Neuromorphological correlates of mood disorders: focus on cerebral ventricular enlargement. 127
Relationship of IQ to neuropsychological tasks involving prefrontal cortex in schizophrenia. 126
Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. 126
Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. 126
DIRECT TRANSITION TO LONG-ACTING RISPERIDONE--ANALYSIS OF LONG-TERM EFFICACY. 125
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. 125
Is ventricular enlargement a variable of interest for family studies in schizophrenia? 125
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. 124
The factor structure analysis for the positive and negative syndrome scale (PANSS) in pharmacogenetics and pharmacogenomics studies. 124
Totale 16.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.856
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021472 0 0 0 0 0 0 0 0 0 0 368 104
2021/20221.439 113 267 26 66 32 65 69 90 82 166 132 331
2022/20231.589 218 24 17 163 129 430 1 179 281 17 56 74
2023/20241.464 95 35 115 109 73 376 61 51 277 28 19 225
2024/20252.880 38 39 42 340 361 238 216 95 257 240 613 401
2025/20265.440 663 765 388 829 548 468 759 172 260 499 89 0
Totale 24.912